GlassScriptPhysician profile
Syed H Anwar
NPI 1477622819
$20,136.57
in general payments reported to CMS, 2019-2025
44 companies · $3,274 in 2025
The $3,274 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,913 · 2020: $1,684 · 2021: $1,988 · 2022: $3,217 · 2023: $3,472 · 2024: $3,589 · 2025: $3,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,912 · Education: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,911.80 |
| Education | $422.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $2,101.88 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $2,080.74 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $1,713.35 | 2019-2025 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $1,436.73 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,419.26 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $1,357.86 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,334.94 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $1,299.24 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $994.91 | 2020-2025 | Caplyta |
| Allergan, INC. | $666.54 | 2019-2020 | |
| Harmony Biosciences LLC | $650.34 | 2022-2025 | Wakix |
| Neuronetics, INC. | $582.96 | 2024 | Neurostar Tms Therapy System |
| Axsome Therapeutics, INC. | $515.72 | 2022-2025 | Auvelity, Sunosi |
| Indivior INC. | $513.89 | 2019-2024 | Perseris |
| Alkermes, INC. | $406.64 | 2020-2025 | Aristada, Lybalvi, Vivitrol |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $396.32 | 2022-2024 | Azstarys, Adlarity |
| Tris Pharma INC | $297.64 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Almatica Pharma LLC | $292.77 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $275.88 | 2021-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $258.85 | 2019-2025 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $238.95 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $200.86 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $184.65 | 2022-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $106.33 | 2019-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $88.69 | 2020-2025 | Xelstrym, Secuado |
| Eisai INC. | $83.99 | 2020-2022 | |
| Shire North American Group INC | $79.70 | 2019 | |
| Braeburn INC. | $75.12 | 2023-2024 | Brixadi |
| Bausch Health US, LLC | $74.43 | 2019-2023 | Aplenzin, Wellbutrin |
| Novo Nordisk INC | $59.26 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $46.92 | 2022-2023 | Belsomra |
| Avanir Pharmaceuticals, INC. | $43.06 | 2019 | |
| Jazz Pharmaceuticals INC. | $36.55 | 2019-2020 | |
| Rhodes Pharmaceuticals L.P. | $31.26 | 2019 | |
| Uswm, LLC | $29.93 | 2021 | |
| Vertical Pharmaceuticals, LLC | $24.77 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $22.72 | 2025 | Jornay Pm |
| Livanova USA, INC. | $21.52 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Orexo US, INC. | $18.14 | 2019 | |
| Acadia Pharmaceuticals INC | $17.20 | 2020 | |
| Aytu Biopharma, INC. | $15.94 | 2021 | |
| Currax Pharmaceuticals LLC | $14.36 | 2022 | |
| Owp Pharmaceuticals, INC. | $12.91 | 2019 | |
| Biodelivery Sciences International, INC. | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Anwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.